Orphan Synergy Europe - Pharma News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

07.09.17	OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio (Businesswire)
06.09.17	OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer (Businesswire)
31.08.17	OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017 (Businesswire)
23.06.17	OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer (Businesswire)
14.06.17	OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders (Businesswire)
23.05.17	Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist (Businesswire)
24.01.17	OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
28.11.16	OSE Immunotherapeutics Appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology (Businesswire)
17.11.16	OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology (Businesswire)
15.11.16	Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases (Businesswire)
15.11.16	Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases (Businesswire)
15.11.16	OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest (Businesswire)
04.11.16	OSE Immunotherapeutics: Total Number of Voting Rights and Shares (Businesswire)
24.10.16	OSE Immunotherapeutics to Present at 2016 MedStart Up Days (Businesswire)
04.10.16	OSE Immunotherapeutics to Present the Preclinical Data of Its New Checkpoint Inhibitor Effi-DEM on SIRP-a/CD47 Strategic Pathway at the 2016 Immune Checkpoint Inhibitors Conference (Businesswire)
20.09.16	OSE Immunotherapeutics to Present Atalante 1, the Registration Clinical Trial of Tedopi®, Ongoing in the U.S. and in Europe, at the World Conference on Lung Cancer (WCLC) (Businesswire)
15.09.16	OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director (Businesswire)
08.09.16	OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones (Businesswire)
06.09.16	OSE Immunotherapeutics: Total Number of Voting Rights and Shares (Businesswire)
30.08.16	OSE Immunotherapeutics Will Present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City, September 11-13, 2016 (Businesswire)
05.07.16	OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases (Businesswire)
20.06.16	OSE Immunotherapeutics Presents Significant Preclinical Results for New Generation Checkpoint Inhibitor, Effi-DEM, at the International Conference (Businesswire)
09.06.16	OSE Immunotherapeutics: Publication of the 2015 Reference Document (Businesswire)
31.05.16	OSE Pharma and Effimune Shareholders Approve Merger to Create OSE Immunotherapeutics (Businesswire)
19.05.16	OSE Pharma and Effimune Announce the Launch of a Non-Interventional Study in Hepatocellular Carcinoma under a Private-Public Collaborative Program (Businesswire)
18.05.16	Dominique Costantini, Co-Founder of OSE Pharma, Invited to « Bpifrance Inno Génération » in Paris, May 25 & 26, 2016 (Businesswire)
12.05.16	OSE Pharma : Presentation of the Future Entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum » (Businesswire)
27.04.16	OSE Pharma SA: Availability of Preparatory Documents for the Combined General Meeting of May 31, 2016 (Businesswire)
15.04.16	OSE Pharma and Effimune Announce the Signing of the Merger Treaty to Create OSE Immunotherapeutics (Businesswire)
11.04.16	OSE Pharma: Fifth Country Opens Recruitment in the Global Pivotal Phase 3 Trial of the Immunotherapy Tedopi® with Initiation in Hungary (Businesswire)
04.04.16	OSE Pharma to Join Workshop (Businesswire)
29.03.16	OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016 (GlobeNewswire)
29.03.16	OSE Pharma to Attend the Small & Midcap Event in Paris on 11 & 12 April, 2016 (Businesswire)
21.03.16	OSE Pharma: 2015 Annual Results in Line with Forecasts, and Significant Clinical Advances (Businesswire)
24.02.16	OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player (Businesswire)
22.02.16	OSE Pharma SA: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced non-small cell lung cancer (Businesswire)
04.02.16	OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer (Businesswire)
06.01.16	OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
05.01.16	OSE Pharma Announces Its Events for Q1 2016 (Businesswire)
23.12.15	OSE Pharma Announces Selection of 70 International Clinical Centers to Participate in Its Pivotal Phase 3 Trial of Tedopi® for Patients Diagnosed with Advanced Non-Small Cell Lung Cancer (NSCLC) (Businesswire)
14.12.15	OSE Pharma to Participate to Biotech Showcase™ During JP Morgan Healthcare Conference (Businesswire)
07.12.15	OSE Pharma Admitted to Long-Only Deferred Settlement Service (Businesswire)
19.11.15	OSE Pharma Successfully Completes the Manufacturing of the Clinical Batches for Its Pivotal Phase 3 Clinical Trial with Tedopi® (Businesswire)
02.11.15	OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi® (Businesswire)
20.10.15	OSE Pharma to attend BIO-Europe 2015 (Businesswire)
29.09.15	OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015 (GlobeNewswire)
16.09.15	OSE Pharma Enters Euronext Index CAC® Small, CAC® Mid & Small and CAC® All-Tradable (Businesswire)
14.09.15	Ose Pharma to Attend BioPharm America September 15th to 16th, 2015, Boston, United-States (Businesswire)
10.09.15	OSE Pharma SA: Results for the First Half of 2015 in Line with Forecasts and Major Clinical Advances (Businesswire)
09.09.15	OSE PHARMA unveils Clinical and immunological outcomes in patients with brain metastases treated with Tedopi® in a phase 2 trial presented at the World Conference on Lung Cancer (WCLC) in Denver, USA (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.78	3.85 %	K V
CieFinRichemont	139.05	3.58 %	K V
UBS Group	29.21	2.64 %	K V
Sika	217.70	2.25 %	K V
Lonza Grp	541.80	1.46 %	K V
Swiss Re	132.60	-0.08 %	K V
Swisscom	504.00	-0.10 %	K V
Sonova Hldg	294.30	-0.71 %	K V
Nestle	74.02	-0.91 %	K V
Givaudan	3’888.00	-1.44 %	K V